Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell–directed therapies
Paola Ghione, Juan J. Gu, Kristopher Attwood, Pallawi Torka, Shipra Goel, Suchitra Sundaram, Cory Mavis, Michael W. Johnson, Roshneke Thomas, Kenneth McWhite, Andrea Darrall, Joseph DeMarco, Jessica Kostrewa, Alice Mohr, Leah Rivas, Mirdza E. Neiders, Lakshmanan Suresh, Brahm H. Segal, Elizabeth A. Griffiths, Vince Ramsperger, Long Shen, Francisco J. Hernandez‐Ilizaliturri
Abstract
Following a similar report on multiple myeloma, Ghione and colleagues report the expected observation that patients with non-Hodgkin lymphoma (NHL) receiving anti-B cell therapies have markedly reduced antibody responses to COVID-19 immunization. Although there is no information regarding T-cell immunity, this suggests that while vaccination is certainly still recommended for this population, patients should be strongly encouraged to maintain social distancing precautions and should be revaccinated after an appropriate interval from the end of their antilymphoma therapy.